A randomized pharmacological fMRI trial investigating d-cycloserine and brain plasticity mechanisms in learned pain responses

Journal Article (2022)
Author(s)

Mia A. Thomaidou (Universiteit Leiden)

Joseph S. Blythe (Universiteit Leiden)

Dieuwke S. Veldhuijzen (Universiteit Leiden)

Kaya J. Peerdeman (Universiteit Leiden)

Johan (Hans) P.A. van Lennep (Universiteit Leiden)

Erik J. Giltay (Universiteit Leiden)

Henk R. Cremers (Universiteit van Amsterdam)

A.W.M. Evers (TU Delft - Human Factors, Universiteit Leiden, Leiden University Medical Center)

Research Group
Human Factors
Copyright
© 2022 Mia A. Thomaidou, Joseph S. Blythe, Dieuwke S. Veldhuijzen, Kaya J. Peerdeman, Johan (Hans) P.A. van Lennep, Erik J. Giltay, Henk R. Cremers, A.W.M. Evers
DOI related publication
https://doi.org/10.1038/s41598-022-23769-7
More Info
expand_more
Publication Year
2022
Language
English
Copyright
© 2022 Mia A. Thomaidou, Joseph S. Blythe, Dieuwke S. Veldhuijzen, Kaya J. Peerdeman, Johan (Hans) P.A. van Lennep, Erik J. Giltay, Henk R. Cremers, A.W.M. Evers
Research Group
Human Factors
Issue number
1
Volume number
12
Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Abstract

Learning and negative outcome expectations can increase pain sensitivity, a phenomenon known as nocebo hyperalgesia. Here, we examined how a targeted pharmacological manipulation of learning would impact nocebo responses and their brain correlates. Participants received either a placebo (n = 27) or a single 80 mg dose of d-cycloserine (a partial NMDA receptor agonist; n = 23) and underwent fMRI. Behavioral conditioning and negative suggestions were used to induce nocebo responses. Participants underwent pre-conditioning outside the scanner. During scanning, we first delivered baseline pain stimulations, followed by nocebo acquisition and extinction phases. During acquisition, high intensity thermal pain was paired with supposed activation of sham electrical stimuli (nocebo trials), whereas moderate pain was administered with inactive electrical stimulation (control trials). Nocebo hyperalgesia was induced in both groups (p < 0.001). Nocebo magnitudes and brain activations did not show significant differences between d-cycloserine and placebo. In acquisition and extinction, there were significantly increased activations bilaterally in the amygdala, ACC, and insula, during nocebo compared to control trials. Nocebo acquisition trials also showed increased vlPFC activation. Increased opercular activation differentiated nocebo-augmented pain aggravation from baseline pain. These results support the involvement of integrative cognitive-emotional processes in nocebo hyperalgesia.